Variable | Grade II–IV, acute GVHD | Chronic GVHD | Relapse | NRM | LFS | OS | GRFS | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
Donor source | ||||||||||||||
MMUD | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
CBT | 1.32 (1–1.74) | 0.052 | 0.94 (0.68–1.3) | 0.69 | 1.35 (1–1.83) | 0.05 | 2.09 (1.46–2.99) |  < 0.0001 | 1.68 (1.34–2.12) |  < 0.0001 | 1.7 (1.33–2.17) |  < 0.0001 | 1.49 (1.21–1.83) | 0.0002 |
Patient age (per 10 years) | 1.11 (1.02–1.21) | 0.02 | 1.06 (0.96–1.17) | 0.24 | 0.99 (0.9–1.08) | 0.81 | 1.31 (1.18–1.45) |  < 0.001 | 1.12 (1.05–1.2) |  < 0.001 | 1.19 (1.11–1.28) |  < 0.001 | 1.07 (1.01–1.14) | 0.02 |
Pre-HCT disease status | ||||||||||||||
CR1 | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
CR2 | 1.05 (0.81–1.35) | 0.72 | 1.08 (0.8–1.45) | 0.63 | 1.07 (0.78–1.48) | 0.67 | 1.3 (0.97–1.74) | 0.08 | 1.2 (0.97–1.48) | 0.10 | 1.26 (1.01–1.58) | 0.04 | 1.14 (0.94–1.38) | 0.20 |
Advanced | 0.78 (0.57–1.08) | 0.13 | 0.95 (0.61–1.5) | 0.84 | 2.89 (2.19–3.83) |  < 0.001 | 2.03 (1.47–2.8) |  < 0.001 | 2.42 (1.96–2.99) |  < 0.001 | 2.57 (2.07–3.21) |  < 0.001 | 1.81 (1.48–2.21) |  < 0.001 |
Cytogenetics | ||||||||||||||
Good risk | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
Intermediate risk | 1.22 (0.75–2) | 0.42 | 0.75 (0.45–1.24) | 0.26 | 1.59 (0.77–3.31) | 0.21 | 0.81 (0.48–1.35) | 0.41 | 1.09 (0.72–1.65) | 0.69 | 1.07 (0.69–1.66) | 0.75 | 0.94 (0.66–1.34) | 0.73 |
Adverse risk | 1.37 (0.8–2.34) | 0.25 | 0.69 (0.37–1.26) | 0.22 | 3.78 (1.79–7.98) |  < 0.001 | 0.75 (0.41–1.36) | 0.34 | 1.74 (1.12–2.71) | 0.01 | 1.48 (0.93–2.36) | 0.10 | 1.36 (0.92–1.99) | 0.12 |
Unknown risk | 1.32 (0.79–2.19) | 0.29 | 0.88 (0.52–1.5) | 0.64 | 1.92 (0.92–4) | 0.08 | 0.85 (0.5–1.44) | 0.54 | 1.23 (0.81–1.88) | 0.33 | 1.2 (0.77–1.87) | 0.42 | 1.18 (0.82–1.7) | 0.36 |
Donor gender | ||||||||||||||
Male donor | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
Female donor | 0.82 (0.67–1.01) | 0.06 | 0.9 (0.7–1.15) | 0.40 | 0.94 (0.74–1.2) | 0.62 | 0.87 (0.69–1.11) | 0.26 | 0.9 (0.76–1.06) | 0.22 | 0.91 (0.76–1.08) | 0.29 | 0.83 (0.71–0.97) | 0.02 |
Conditioning regimen | ||||||||||||||
MAC | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
RIC | 0.89 (0.69–1.14) | 0.34 | 0.86 (0.64–1.16) | 0.33 | 1.27 (0.97–1.64) | 0.08 | 0.6 (0.46–0.8) |  < 0.001 | 0.86 (0.71–1.03) | 0.10 | 0.79 (0.65–0.97) | 0.02 | 0.85 (0.71–1.01) | 0.06 |
KPS ≥ 90 | 0.74 (0.58–0.94) | 0.02 | 1.19 (0.86–1.64) | 0.30 | 0.95 (0.72–1.24) | 0.69 | 0.8 (0.6–1.05) | 0.10 | 0.87 (0.72–1.05) | 0.16 | 0.86 (0.7–1.05) | 0.15 | 0.85 (0.71–1.02) | 0.09 |
Centre (frailty) |  |  < 0.001 |  |  < 0.001 |  | 0.24 |  | 0.03 |  | 0.30 |  | 0.18 |  | 0.10 |